Hypha实验室和Tryptomics正在加速开发制药级健康产品的最佳蘑菇菌株,预计到2026年将出现新的菌株。 Hypha Labs and Tryptomics are accelerating development of optimized mushroom strains for pharmaceutical-grade wellness products, with new strains expected by 2026.

Hypha实验室和Tryptomics已经启动了其伙伴关系的第二阶段,将Hypha的Mushroom加速器TM平台与Trypomics的质量控制、基因组学和代谢技术结合起来,以加速生物反应器优化蘑菇菌株的开发。 Hypha Labs and Tryptomics have launched Phase II of their partnership, combining Hypha’s Mushroom Accelerator™ platform with Tryptomics’ quality control, genomics, and metabolomics technologies to accelerate development of bioreactor-optimized mushroom strains. 这种合作使得能够利用内部测试、第三方核查、重复生物反应器和先进的遗传分析,在短短8天内迅速、可复制地生产生物可获的蘑菇成分。 The collaboration enables rapid, reproducible production of bioavailable mushroom ingredients in as little as eight days, using in-house testing, third-party verification, duplicate bioreactors, and advanced genetic analysis. 第一批新菌株预计将于2026年启动,支持可扩展的医药级健康产品。 The first new strains are expected to launch in 2026, supporting scalable, pharmaceutical-grade wellness products. Hypha实验室还在推动一项条例A+的公开提议,从消费设备扩大到大规模成分生产。 Hypha Labs is also advancing a Regulation A+ public offering to expand from consumer devices to large-scale ingredient production.